next generation pcr, leading by digital pcr, cast pcr and...
TRANSCRIPT
Next generation PCR, leading by digital PCR, Cast PCR and OpenArray ® PCR, Cast PCR and OpenArray ®
Kevin MunnellySr. Director, qPCR PlatformLife Technologies
Agenda• Introduction
• castPCR Overview
• OpenArray Overview− Red Blood Cell Genotyping Study− Breast Cancer Biomarker Study− miRNA in Plasma Study
2
− miRNA in Plasma Study− Single Cell Gene Expression Study in Stem cells
• Digital PCR Overview− Detection of West Nile Virus
| Life Technologies Proprietary & Confidential | 5/12/2011
Individual Assays in TubesFlexible, any instrument
TaqMan® Assay Plates5 formats – FAST & Std96 well optical platesCustom Plated; 135 inventoried
Choice of 4 formats
GeneAssist ToolsSearch for assays in agiven pathway or workflow
Software tools simplifyAssay selection & data analysis
UmapItSearch for assays that map to microArray probes
Genomic Assays Portfolio
3
TaqMan® Arrays384 well microfludic cards>80 pre-defined pathways Custom AssaysMedium and large projects
Custom Plated; 135 inventoriedPredefined gene sets
map to microArray probes
DataAssist, StatMinerData analysis softwareStatistical analysis
TaqMan OpenArray® Plates3072 well array plate; highestThroughput/lowest cost per rxn
SNP Browser
AutoCaller SNP Analysis
CopyCaller CNV Analysis
Next-Gen qPCR technology now..
TaqMan assays for any sample, any size research project!
4
• mRNA, microRNA, epigenetic target discovery & validation• DNA variant discovery & validation• Toxicity• Dosing profiles
• Clinical screening with consolidated human pathogen panels• Host-pathogen response• Antibiotic screening
• Genetic epidemiology• Copy number variation• Gene discovery• siRNA knockdown validation• Stem cell biomarkers
Drug Development Translational Clinical Research
Pathogen ID and Quantification
Consolidation and Standardization of Molecular Information Across Multiple Markets
• Biomarker selection and validation• Companion diagnostic development• Predisposition screening• Treatment selection• Recurrence monitoring
Life Science Research
5
• Dosing profiles• Mechanism of action
• Recurrence monitoring
Multiple applications enabled by spatially multiplexed, multi-specimen quantitative PCR analysis
A New Era in High-Productivity qPCR
● Integrated TaqMan® Array block
● Responsive touch-screen interface
6
● Rapid block change
● Intuitive software with ReadiApp™ Application and QuickStart functions
● OptiFlex™ System
Most Flexible Optical TechnologyOptiFlex™ System
Emission
Excitation
● Maximal multiplexing capability− 6x6 excitation and emission filters
for up to 21 combinations− Run TaqMan® and SYBR®
chemistry-based assays on the same run
7
• Sensitivity and Uniformity
− Read 384-wells at volumes to 1uL
(TaqMan® Array Cards)
− Detect 1.5 fold change
− Enables consistent results: run-to-
run and instrument-to-instrument
How to Detect Cancer Early?
Early Late
Cancer invasionAngiogenesisMetastasis
Diagnosis
Premalignant progression
8
• Circulating tumor cells (CTCs) in blood carry mutations.
• CTCs could be used as diagnostic markers. • No. of CTCs in blood is low. Highly specific
and sensitive assays are needed for early cancer detection.
AAAA
G
A
Normal DNA
Mutant DNA
A pair of assays: mutation assay and a gene reference assay
Both assays with FAM MGB probe
Mutation Assay− Allele specific primer (ASP)
GC
Mutation specific PCR
ASP
LSP
LST
MGBASB
Competitive Allele-Specific TaqMan ® PCR
castPCR™: C ompetitive A llele-S pecific T aqMan® PCR
9
− Allele Specific MGB blocker (ASB)− locus-specific TaqMan® probe (LST)− locus-specific PCR primer (LSP)
Gene Reference Assay− Standard TaqMan® assay− Two locus specific primers− Locus specific TaqMan® Probe
AMGBASB
CastPCR: TaqMan-like Sensitivity and Dynamic Range
Amplification plot Standard curve
Cq
25
30
35
40
SNP: NRAS-181C>A
Cq
1.00
∆Rn
Y = -3.5x + 34.2R2 = 0.9999
107 106 105 104 103 102 10 1 copies
10
DNA copy number (log10)
Cq
0
5
10
15
20
0 1 2 3 4 5 6 70 5 10 15 20 25 30 35 40 45
Cycles
Cq0.10
0.01
∆Rn
Assay Specificity – Conventional AS-PCR vs. castPCR
50.048.228.5G
ATC
50.048.228.5G
ATC
37.328.127.2G
ATC
37.328.127.2G
ATC
Conventional allele-specific-PCR CastPCR
Primer base at 3′ Primer base at 3′
11
28.15050T
5028.548.5A
50.048.228.5G
28.15050T
5028.548.5A
50.048.228.5G
27.330.528.1T
37.128.128.5A
37.328.127.2G
27.330.528.1T
37.128.128.5A
37.328.127.2G
gDN
A te
mpl
ate
Ave. ∆∆∆∆Cq (Cq _mm – Cq_pm) = 4.1 Ave. ∆∆∆∆Cq (Cq _mm – Cq_pm) = 21.1gD
NA
tem
plat
e
SNP: hCV11711720
Specificity of CastPCR Assays – Tumor gDNA Spiking
20
30
40
Cq
y = -3.572x + 38.9
R2 = 0.999
A1/A1
A2/A2A2/A2
12
Mutant 1 10 102 103 104 105 106 copies
Conclusion: KRAS castPCR assays can detect up to 1 copy of mutant DNA in the background of 2.5 µg wild-type genomic DNA
Wild-type 2.5 2.5 2.5 2.5 2.5 2.5 2.5 µg
20
A1/A1
Detection of Mutations in Heterogeneous Tumor Samples
• Study 1: KRAS Mutation in Colorectal FFPE Samples ( n=21)
G12A G12C G12D G12R G12S G12V G13D WT
castPCR™ 2 1 4 0 0 4 8 2
Sanger Sequencing
2 1 4 0 0 4 8 2
13
• Study 2: BRAF, KRAS and EGFR Mutation in Cell Line, FFPE and Fresh Frozen tumor samples (n=33)
BRAFEGFR T790M
EGFR L858R
EGFR G719D
EGFR Del E746-A750
(6223)
EGFR Del E746-A749
(6225)
7 KRAS mutations
WT
castPCR™ 1 1 3 1 2 3 18 6
Allele-specificPCR
1 1 2 1 2 3 17 7
Sanger sequencing
1 1 2 1 2 3 17 7
Detection of BRAF 1799T>A Mutation in Plasma of Recurrent Melanoma Cancer Patients
14
Note: 20 ng plasma DNA per PCR reaction
TaqMan® Mutation Detection Assays Product Overview
• 70 castPCR™ assays for:– EGFR (30 mutation + 25 wild type assay)– KRAS (14 mutation + 14 wild type assay)– BRAF (1 mutation + 1 wild type)
• Single assay may cover multiple deletions• Three gene specific reference assays• IPC reagents
Single tube assays(Full launch- July 2011)
Fixed set of TaqMan® Mutation Detection assays in 96-well FAST Plates(Early Access- April 2011)
KRAS-BRAF plate & EGFR plate
15
Data Analysis
• IPC reagents
Real-time PCR instruments
KRAS-BRAF plate & EGFR plate
The OpenArray® System for Real-Time PCR and TaqMan® Genotyping
16
OpenArray® Plates
Hydrophilic
Hydrophobic
17
Data Points per/day/FTE
Genotyping
Gene Expression
�70,000
�32,000
OpenArray Plate Layout
Subarrays 48 (12 x 4)
Through-holes 64 per subarray (8 x 8)
Reaction Volumes
Total 33nL
What is the OpenArray® System?
• The OpenArray Real Time PCR System now delivers the proven, market leading chemistry of TaqMan® products in a faster, more flexible format.
• TaqMan OpenArray Real-Time PCR products enabling dense gene coverage and sample throughput
− 32,000 data points in just one work day
• SYBR® OpenArray Real-Time PCR products offers pathway panels
18
• SYBR® OpenArray Real-Time PCR products offers pathway panels and custom plating enabling unprecedented gene coverage and sample throughput
− 24,000 data points in just one work day
• TaqMan OpenArray Genotyping products utilizes TaqMan chemistry for allelic discrimination
− > 70,000 data points in just one work day
Single-Plex PCR
PCR tests are isolated and independent
19
‘Swappable’ independent tests facilitates rapid optimization and
implementation of pathogen detection panels.
No need to re-optimize test panel if changed
“Plug and play”
TaqMan® SNP Genotyping Assays
- 160,000 validated assays with 20 million associated genotypes (Mapping SNPs)
- 3.5 million HapMap SNPs providing 70% HapMap coverage
4.5 million pre-designed assays for high-density, genome wide coverage pre-mixed at a 40x and 80x concentration
20
- 70,000 coding SNP assays for the detection of SNPs within coding regions, including many putative functional SNPs
- >2,600 Drug Metabolism assays for 220 drug metabolism and transporter genes
SNP Panels
SNP Panel Name Suggested Format SNP Panel Details
Sample Tracking Panel 32-64 Markers identified at U Miami, represented on Illumina and AffySNP panels
Ancestry Informative Marker 128 Markers identified by the Seldin
21
Ancestry Informative MarkerSNP Panel
128 Markers identified by the Seldin Lab at UC Davis
Universal Individual IdentificationSNP Panel
128 Markers identified by the Kidd Lab at Yale
Cytochrome P450SNP Panel
128 Pharmacologically relevant polymorphisms in the cytochrome p450 family of genes
TaqMan® OpenArray® Genotyping Formats
22
Genotyping WorkflowAt Life Technologies
23
At the Researcher’s Lab
Results!
TaqMan® Genotyper Software
24
Red Blood Cell Antigen Genotyping• Serological methods are labor intensive and expensive
• About 5% of transfusion patients lack a common blood group antigen and risk developing an antibody to the missing blood antigen.
− Hemolysis of subsequently transfused blood
• Is there a high throughput method to screen blood donors for antigen genotypes?
25
genotypes?− Molecular genotyping has a better analytic specificity and sensitivity then
serological methods.− High throughput SNP genotyping methods can first screen a donor
population to identify donors of specific blood types and then followed up by a confirmatory serological test.
Hopp K, Weber K, Bellissimo D, Johnson ST, Pietz B. (2010). High-throughput red blood cell antigen genotyping using a nanofluidic real-time polymerase chain reaction platform. Transfusion. 50:40-46.
Study Design• Antigens
− Four antigens chosen for genotype/phenotype concordance study for providing blood to Sickle Cell patients
> Rh E/e; Fya /Fyb; Jka /Jkb ; K/k
− Three antigens and one SNP responsible for silencing expression of the Fy antigen were chosen to detect rare antigen negative phenotypes
> Jsa /Jsb; Joa; Hy; Fy (GATA)
26
− Two antigens selected due to the scarcity of reliable antisera (antiserum)
> Lua /Lub; Doa /Dob
• Patients− 427 African American donors
Results− >99% Reproducibility− 99.7% concordance with predicted phenotype generated by
interpretation of assay genotype results
> 4 discordant resolved by repeat serology
> 1 discordant resolved after repeat genotyping
27
Typical Allelic Discrimination plot generated by the TaqMan® OpenArray® Genotyping Analysis Software
OpenArray Genotyping System • More samples for more genetic power
− Process 24 arrays per day with minimal hands-on time
• Simple workflow − Preloaded with assays of your choice—just add sample, cycle, and
image
• Best experimental flexibility− Choose any combination of TaqMan SNP Genotyping or DME Assays
28
− Choose any combination of TaqMan SNP Genotyping or DME Assays
• Reliable− Uses TaqMan Genotyping Assay chemistry
• Easy-to-understand pricing− No oligo setup fee or hidden costs
• Easy ordering− Online Custom Assay Design Tool and configurator tool
• Powerful Data Analysis− TaqMan® Genotyper Software
TaqMan® Gene Expression AssaysInventoried Assays
Species Assay CountHuman 29,222
Mouse 19,100
29
Mouse 19,100
Rat 10,862
Other (15 species) 2,118
Total 61,302
Minimum 10-pack order for all formats with 10-pack increments
Look forward to a TaqMan® OpenArray Hs Housekeeping Panel
TaqMan OpenArray Pathways Panels• Validated Content
• Gene Selection from literature
• Off the Shelf Product
30 | Life Technologies Proprietary & Confidential | 5/12/2011
OpenArray® Real-Time Formats
OpenArray® Real-Time qPCR Plate, 18
OpenArray® Real-Time qPCR Plate, 56
OpenArray® Real-Time qPCR Plate, 112
A1 1 2 3 4 5 6 7 8
a 1 2 3 4 5 6 7 8
b 9 10 11 12 13 14 15 16
c 17 18 19 20 21 22 23 24
d 25 26 27 28 29 30 31 32
e 33 34 35 36 39 39 39 40
f 41 42 43 44 45 46 47 48
g 49 50 51 52 53 54 55 56
h 57 58 59 60 61 62 63 64
Subarray:
31
OpenArray® Real-Time qPCR Plate, 112
OpenArray® Real-Time qPCR Plate, 168
OpenArray® Real-Time qPCR Plate, 224
Gene Expression WorkflowAt Life Technologies
32
At the Researcher’s Lab
Results!
Confidential4.0
6.0
8.0
Open
Arr
ay
OpenArray vs ABI7900(Colon Tumor vs Normal Colon)
Ope
nArr
ay (∆∆
Ct)
R2=0.99
Ct (OpenArray)
Ct(7900)
20
25
30
35
15 20 25 30
OpenArray (Ct)
AB
7900
(C
t)
Correlation=0.996
Platform Comparisons
33nL Reactions vs. 20 uL Reactions
33 33
-6.0
-4.0
-2.0
0.0
2.0
-6.0 -4.0 -2.0 0.0 2.0 4.0 6.0 8.0
∆∆
CtO
pen
Arr
ay
∆∆Ct 7900
Correlation =0.98
ABI7900 (∆∆Ct)
Ope
nArr
ay (
Correlation=0.974R
otor
-Gen
e (C
t)
OpenArray (Ct)
Gene Expression: Methods• 44 patients enrolled at 2 medical facilities
− Undergoing mastectomy: cancer, ipsi- and contra lateral normal tissues were collected (histologically examined to ensure correct histology)
• 20 patients enrolled at private practices− Undergoing breast reduction (tissues histologically examined, less than
60% fat content)
• Samples were frozen within 1 hr post surgery
34
• Samples were frozen within 1 hr post surgery− RNA isolated using standard homogenization and column methods− Analyzed to confirm
> 28S/18S ratio = 1 ±0.2 (using Agilent Bioanalyzer)
> A260/A280 ratio > 1.6
Comparison of Breast Cancer to Healthy Control Tissue Discovers Novel Markers
withPotential for Prognosis and Early
Detection
Samples: 9 normal controls and 13 invasive tumorsNormalization: 3 Housekeeping genesConclusions:
- High correlation with previous qPCR data
35
- High correlation with previous qPCR data- Identified 101 new genes normal/breast cancer- Better patient stratification
“Applying the same criterion as for the
original set … both our original analysis and
BioTrove analysis of the reduced set would
have selected the same differentially
expressed genes.”
Schummer M, et al. (2010) PLoS ONE 5(2): e9122. doi:10.1371/journal.pone.0009122
Comparison of Breast Cancer to Healthy Control Tissue Discovers Novel Markers withPotential for Prognosis and Early Detection
“
“
36 | Life Technologies Proprietary & Confidential | 5/12/2011
“
Schummer M, et al. (2010) PLoS ONE 5(2): e9122. doi:10.1371/journal.pone.0009122
Next-Gen miRNA Profiling PlatformTaqMan® OpenArray® miRNA Panels
• Broad coverage− Run three samples per OpenArray® plate− 818 assays per sample (758 unique assays)
> 3 positive and 1 negative/process control per subarray
• High-throughput − 9 samples per ~2.5 hr instrument run Sample
Sample 3
37
− 9 samples per ~2.5 hr instrument run− 36 samples per 8hr working day
• Cost effective− Rapid sample screening with minimal hands-on time
• Minimal sample requirement− 100ng of total RNA recommended for a full profile
Sample 1
Sample 2
OpenArray ® miRNA Profiling Workflow
Sample 1
Sample 2
Megaplex™ RT Primer Pool A
Megaplex™ Preamp Primer
Pool A
OpenArray® MicroRNA Panel
Reverse Transcription•TaqMan® MicroRNA RT Kit
Preamplification•TaqMan® PreAmp Master Mix
qPCR•GeneAmp Fast MM
38
Sample 3
3 Samples≈ 750 Targets
Megaplex™ RT Primer Pool B
Megaplex™ Preamp Primer
Pool B
Sample 1 Total RNA Sample
OpenArray® 384-well Sample Plate
150 min. 90 min.
150 min.*(*up to 3 arrays/9 samples
run simultaneously)
Total time = < 8 hours
30 min.
Concordance With Individual AssaysOpenArray ddCq(Brain-Lung) vs. Single Assay ddCq(Br ain-Lung)
y = 0.9198x - 0.1703
R2 = 0.9476
0
2
4
6
Sin
gle
Ass
ay d
dCq
(Bra
in-L
ung)
39
-8
-6
-4
-2
0
-8 -6 -4 -2 0 2 4 6 8
OpenArray ddCq (Brain-Lung)
Sin
gle
Ass
ay d
dCq
(Bra
in-L
ung)
Human Plasma: Full Workflow Reproducibility
y = 0.9448x + 1.3014
R² = 0.9508
0
5
10
15
20
25
30
0 10 20 30
S1 vs S2
y = 0.9507x + 1.1552
R² = 0.9341
0
5
10
15
20
25
30
0 10 20 30
S1 vs S3cy = 0.9994x - 0.0128
R² = 0.973
0
5
10
15
20
25
30
0 10 20 30
S2 vs S3c
R2 S1 S2 S3C S4 S5 S8
S1 1.0000
• 6x 200ul aliquots from the same human plasma sample• RNA isolated using mirVana™ PARIS™ Kit• Ran through protocol independently• Single replicates of each sample run on OpenArray• R2 plotted for Ct <25
40 | Life Technologies Proprietary & Confidential | 5/12/2011
y = 0.9295x + 1.7689
R² = 0.9335
0
5
10
15
20
25
30
0 10 20 30
S1 vs S4
y = 0.9189x + 2.0114
R² = 0.9302
0
5
10
15
20
25
30
0 10 20 30
S1 vs S5
y = 0.9332x + 1.6659
R² = 0.9139
0
5
10
15
20
25
30
0 10 20 30
S1 vs S8
y = 0.9785x + 0.6125
R² = 0.9683
0
5
10
15
20
25
30
0 10 20 30
S2 vs S4
y = 0.9602x + 0.9855
R² = 0.9662
0
5
10
15
20
25
30
0 10 20 30
S2 vs S5
y = 0.9682x + 0.8481
R² = 0.9604
0
5
10
15
20
25
30
0 10 20 30
S3c vs S4
y = 0.9945x - 0.1071
R² = 0.9612
0
5
10
15
20
25
30
0 10 20 30
S3c vs S5
y = 0.9724x + 0.4203
R² = 0.9496
0
5
10
15
20
25
30
0 10 20 30
S3c vs S8
y = 0.9828x + 0.3159
R² = 0.9692
0
5
10
15
20
25
30
0 10 20 30
S4 vs S5
y = 0.9691x + 0.6817
R² = 0.966
0
5
10
15
20
25
30
0 10 20 30
S4 vs S5y = 0.9639x + 0.8227
R² = 0.9598
0
5
10
15
20
25
30
0 10 20 30
S5 vs S8y = 0.9826x + 0.4829
R² = 0.9566
0
5
10
15
20
25
30
0 10 20 30
S2 vs S8
S1 1.0000
S2 0.9508 1.0000
S3 0.9341 0.9730 1.0000
S4 0.9335 0.9683 0.9604 1.0000
S5 0.9302 0.9662 0.9679 0.9692 1.0000
S8 0.9139 0.9566 0.9660 0.9660 0.9777 1.0000
• All R2 above 0.9• Average 0.966
miRNA Detection By qRT-PCR In Single mESCs
41 | Life Technologies Proprietary & Confidential | 5/12/2011
Violin plot showing the distribution of miRNA expression levels. miRNAshave been sorted according to expression frequency and all zero valueshave been removed showing a correlation between expression level andexpression frequency.
Hierarchical clustering analysis of theexpression of 61 miRNAs in 24 single cellsreveals a variety of expression patterns.
Courtesy of Fred Kolling IV et al, Dpt Molecular and Cell Biology, University of Connecticut
Cell Heterogeneity: Materials and Methods
• Samples: FACS-sorted CellSensor MA-180 cells(single cells, n=420; 10 cells, n=20, 100 cells, n=20, no cells, n=20)
Treatment: ±EGF, activation of ras and MAPK pathwaysOA: 56 Taqman assays
42
Sample protocol: optimized Cells-to-Ct and gene-specific pre-amplificationqPCR platform: AB7900 and OpenArrayTest sites: Austin and WoburnTotal # of samples tested: 480/treatment
Single Cell-to-C T kit is compatible with OpenArray Platform
Product Name Part Number
Package
Single Cell Lysis Kit 4458235 100 rxn
Single Cell-to-CT™ Kit 4458236 400 rxn
Single Cell-to-CT™ Kit 4458237 50 rxn
Additions to a single tube
43 | Life Technologies Proprietary & Confidential |
Single Cell
Reverse Transcription
***Taqman Multiplex
PreAmplification
Taqman OpenArray Real-Time
qPCR
Additions to a single tube
Single Cell-to-CT®
* **Pre-Amp primers provided through Speedboat Group
Single Cell Gene Expression Profiles (OA)
44
The analysis of single cells clearly show cellular heterogeneity for these genes
45 | Life Technologies Proprietary & Confidential | 5/12/2011
Digital PCR™ at Life Technologies
• Dilute-Distribute-Amplifiy-Count
Digital PCR™ OpenArray ®
• 3072 thru-holes• Runs TaqMan ®Chemistry
• MxN Flexibility
•Acquired Cytonix Corp. •Acquired BioTrove for the
46
•Acquired Cytonix Corp. for IP related to digital polymerase chain reaction technology
•Acquired BioTrove for the OpenArray technology
Digital OpenArray
• Flexible Digital solutions using TaqMan
Analog PCR (qPCR) and Digital PCR: Absolute Quantitation
Analog Digital
47 8/16/10© 2010 Life Technologies. All Rights Reserved. | Proprietary and Confidential.
47
... relative quantitation
# positive, negative wells
# copies present in sample
Cycle
Rn
Ct value
Standards, endogenous
controls
Results from other samples
∆Ct, ∆∆Ct, …
... absolute quantitation
OpenArray Digital PCR Product Concept
Digital PCR answer:# copies / uL
Customer sample
TaqMan® OpenArray® Digital PCR
Master Mix (2X)OpenArray® Digital PCR
Software
New Digital PCR Products
48 8/16/10© 2010 Life Technologies. All Rights Reserved. | Proprietary and Confidential.
48
OA Real-Time PCR System
C t b y P o s i t i o n
1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0
5
1 0
1 5
2 0
2 5
3 0
AccuFill(or AutoLoader I)
Primary analysis
TaqMan assay
say
TaqMan OpenArray ®
Digital PCR Master MixOpenArray ® Digital
PCR Plates
Set-up file
Software
Problem: WNV• Blood/tissue samples in early stages of infection present at low levels
− Sometimes, availability of sample volume is low further confounding the issue
• 50ul Standard qPCR yields consistent results with Ct greater than 36.
• Is the detection real and how many copies of WNV are in the actual
49
• Is the detection real and how many copies of WNV are in the actual sample?
| Life Technologies Proprietary & Confidential | 5/12/2011
dPCR of West Nile Virus (Standard curve) and HIV Samples
A
B
C
D
EF
Z21
1 2 3 4 5 6 7 8 9 10 11 12
HIV+ MM+ABI03
HIV+ MM+HIV4Rev
HIV+ MM+ABI12
WNV dil 1-5 +WNV 1-28098 WNV dil 1-5 +
WNV 2-28099
50
DNTC
dPCR AnalysisGroup
Average Copies per Reaction
Lower Confidence
Interval
Upper Confidence
Interval
Total Replicates
Total Negatives
Confidence Interval Range
WNV1_WNV1-28098 1.5562 1.2547 1.9301 128 27 1.2547 - 1.9301WNV2_WNV1-28098 0.9808 0.7808 1.232 128 48 0.7808 - 1.2320WNV3_WNV1-28098 0.5894 0.4529 0.7669 128 71 0.4529 - 0.7669WNV4_WNV1-28098 0.3087 0.2203 0.4327 128 94 0.2203 - 0.4327WNV5_WNV1-28098 0.1515 0.0954 0.2406 128 110 0.0954 - 0.2406NTC_WNV1-28098 NaN NaN NaN 128 128 NaN - NaN
51
28098 NaN NaN NaN 128 128 NaN - NaNWNV1_WNV2-28099 NaN NaN NaN 128 0 NaN - NaNWNV2_WNV2-28099 2.213 1.7699 2.7669 128 14 1.7699 - 2.7669WNV3_WNV2-28099 1.418 1.1425 1.7601 128 31 1.1425 - 1.7601WNV4_WNV2-28099 0.8267 0.6518 1.0484 128 56 0.6518 - 1.0484WNV5_WNV2-28099 0.3634 0.265 0.4982 128 89 0.2650 - 0.4982NTC_WNV2-28099 NaN NaN NaN 128 128 NaN - NaNHIVABI03 NaN NaN NaN 512 512 NaN - NaNHIVABI12 NaN NaN NaN 512 512 NaN - NaNHIVHIV4Rev NaN NaN NaN 512 512 NaN - NaN
Summary
OpenArray Systems accelerates molecular analysis
52
� Scalable molecular analysis platform
� Utilizes familiar PCR chemistries
� Eliminates need for complex multiplex PCR assay development
� Enabled reduced time, labor and reagent consumption
Legal StatementNOTICE TO PURCHASER: Limited Use Label License
The products shown in this presentation may be cove red by one or more Limited Use Label License(s). Please refer to the r espective product documentation or the Applied Biosystems website und er www.appliedbiosystems.com for the comprehensive license information.
By use of these products, the purchaser accepts the terms and conditions of all applicable Limited Use Label Licenses. These products are sold for research use only, and are not intended for human o r animal diagnostic or
53
research use only, and are not intended for human o r animal diagnostic or therapeutic uses unless otherwise specifically indi cated in the applicable product documentation or the respective Limited Use Label License(s).
© 2010 Life Technologies Corporation. All rights re served.
The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners. TaqMan is a registered trademark of Roche Molecular Systems, Inc.
Fore research use only. Not intended for human or an imal therapeutic or diagnostic use